ArticleAnnals of the rheumatic diseases2026
Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis.
Article in Annals of the rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Review
- Atypical Interplay of Dermatomyositis, Metastatic Caecal Carcinoma, and Connective Tissue Disease.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesOne-third of patients diagnosed with dermatomyositis harbour an occult cancer, a rare condition named cancer-associated dermatomyositis (CAD). Emerging evidence suggests that genetic alterations in autoantibody-related genes give rise to neoantigens and specific autoantibodies that initiate an autoimmune response characteristic of CAD. This study evaluated the prevalence of such genetic alterations and elucidated molecular mechanisms that may underlie their role in triggering autoimmunity.
methodsFifteen patients with CAD were included in the study. We conducted genomic and transcriptomic analyses of available leukocyte (germline), muscle, skin, and tumour samples. T-cell receptor (TCR) repertoire profiling and multiplex immunophenotyping were performed to characterise immune responses in tumoural and nontumoural tissues.
resultsSomatic mutations and loss of heterozygosity (LOH) in autoantibody-related genes as tripartite motif containing 33, tripartite motif containing 66, MORC family CW-type zinc finger 3 (MORC3), Chromodomain Helicase DNA Binding Protein 4, and IFIH1, interferon-induced helicase C domain-containing protein 1-corresponding to known myositis-specific autoantibodies Anti-transcriptional intermediary factor 1 gamma, anti-nuclear matrix protein 2, (anti-transcriptional intermediary factor 1 gamma (anti-TIF1γ), anti-nuclear matrix protein 2 (anti-NXP2), anti-Mi2, antimelanoma differentiation-associated gene 5 protein), were detected in the majority of tumours from patients with CAD (75%). Tumour-specific missense mutations gave rise to highly immunogenic neoantigens, while LOH resulted in enriched allelic expression not observed in nontumoural lesions (skin and muscle). Immunophenotyping revealed a clonally expanded lymphocyte population within tumours, but not in nontumoural lesions, suggesting a distinct cellular immune response.
conclusionsWe detected highly frequent genetic alterations in autoantibody-related genes, supporting their role in the CAD pathogenic mechanisms. Moreover, our findings suggest that distinct TCR repertoire and immune signatures between tumoural and nontumoural tissues may underlie divergent cancer and dermatomyositis outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.